Results 161 to 170 of about 4,485 (189)
HIV-1 Latency and Latency Reversal: Does Subtype Matter? [PDF]
Viruses, 2019 Cells that are latently infected with HIV-1 preclude an HIV-1 cure, as antiretroviral therapy does not target this latent population. HIV-1 is highly genetically diverse, with over 10 subtypes and numerous recombinant forms circulating worldwide. In spite of this vast diversity, much of our understanding of latency and latency reversal is largely based
Indra Sarabia +2 more
exaly +5 more sources
The role of latency reversal in HIV cure strategies [PDF]
Journal of Medical Primatology, 2022 One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune‐mediated cell death. This is called latency reversal.
Sharon Ruth Lewin
exaly +2 more sources
Novel Latency Reversal Agents for HIV-1 Cure [PDF]
Annual Review of Medicine, 2018 Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate ...
Vicente Planelles, Adam Spivak
exaly +3 more sources
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression [PDF]
Journal of Virology, 2018 Combinations of drugs that affect distinct mechanisms of HIV latency aim to induce robust latency reversal leading to cytopathicity and elimination of the persistent HIV reservoir. Thus far, attempts have focused on combinations of protein kinase C (PKC)
Mark M Painter +2 more
exaly +2 more sources
HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies [PDF]
Cells, 2021 Eradication of latent human immunodeficiency virus (HIV) infection is a global health challenge. Reactivation of HIV latency and killing of virus-infected cells, the so-called “kick and kill” or “shock and kill” approaches, are a popular strategy for HIV
Sushant Khanal +2 more
exaly +3 more sources
Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal [PDF]
ACS Infectious Diseases, 2020 A hallmark of human immunodeficiency type-1 (HIV) infection is the integration of the viral genome into host chromatin, resulting in a latent reservoir that persists despite antiviral therapy or immune response. Thus, key priorities toward eradication of
, Edward Browne, Brian D Strahl
exaly +3 more sources
Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal [PDF]
Cell Chemical Biology, 2018 The persistence of a pool of latently HIV-1-infected cells despite combination anti-retroviral therapy treatment is the major roadblock for a cure. The BAF (mammalian SWI/SNF) chromatin remodeling complex is involved in establishing and maintaining viral
Benjamin Carter +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reversal of Latency as Part of a Cure for HIV-1
Trends in Microbiology, 2016Here, the use of pharmacological agents to reverse HIV-1 latency will be explored as a therapeutic strategy towards a cure. However, while clinical trials of latency-reversing agents LRAs) have demonstrated their ability to increase production of latent HIV-1, such interventions have not had an effect on the size of the latent HIV-1 reservoir ...
Rasmussen, Thomas Aagaard; id_orcid 0000-0001-5354-2442 +2 more
openaire +3 more sources
Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity
European Journal of Medicinal Chemistry, 2023Cells latently infected with human immunodeficiency virus type 1 (HIV-1) prevent people living with HIV-1 from obtaining a cure to the infectious disease. Latency reversing agents (LRAs) such as protein kinase C (PKC) activators and histone deacetylase (HDAC) inhibitors can reactivate cells latently infected with HIV-1.
Takahiro, Ishii +10 more
openaire +2 more sources
The mTOR Complex Controls HIV Latency [PDF]
Cell Host and Microbe, 2016 A population of CD4 T lymphocytes harboring latent HIV genomes can persist in patients on antiretroviral therapy, posing a barrier to HIV eradication.
Michael Bassik +2 more
exaly +3 more sources